* Abcellera Biologics Inc ABCL.OQ reported a quarterly
adjusted
loss of 10 cents per share for the quarter ended in September,
lower than the same quarter last year, when the company reported
EPS of 8 cents. The mean expectation of nine analysts for the
quarter was for a loss of 13 cents per share. Wall Street
expected results to range from -20 cents to -10 cents per share.
* Revenue fell 93.5% to $6.60 million from a year ago;
analysts
expected $11.84 million.
* Abcellera Biologics Inc's reported EPS for the quarter was
a
loss of 10 cents.
* The company reported a quarterly loss of $28.61 million.
* Abcellera Biologics Inc shares had fallen by 10.4% this
quarter and lost 59.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 4% in
the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Abcellera
Biologics Inc is $24.50
This summary was machine generated from LSEG data November 2 at
09:39 p.m. UTC. All figures in US dollars unless otherwise
stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2023 -0.13 -0.10 Beat
Jun. 30 2023 -0.13 -0.11 Beat
Mar. 31 2023 -0.14 -0.14 Met
Dec. 31 2022 -0.01 -0.10 Missed